Teva launches authorized generic version of Pfizer’s Detrol LA
JERUSALEM — Teva Pharmaceutical Industries has launched an authorized generic version of a drug used to treat overactive bladder, the company said Friday.
Teva announced the launch of authorized generic tolterodine tartrate extended-release capsules in the 2-mg and 4-mg strengths. Authorized generics are branded drugs marketed under their generic names at a discounted price, usually under contracts between the branded manufacturers and third-party companies.
The drug is a version of Pfizer’s Detrol LA, which had sales of about $571.5 million during the 12-month period that ended in September, according to IMS Health.
Salix purchase of Santarus completed
RALEIGH, N.C. — Salix Pharmaceuticals has completed its $2.6 billion acquisition of Santarus, Salix said.
The drug maker announced that it had completed the $32-per-share acquisition of Santarus, which the companies announced in November. The combination of the companies’ product portfolios includes 22 marketed products, such as Xifaxan, Glumetza, Zegerid, Relistor and others.
"The acquisition of Santarus is a transformational event for Salix and an important milestone in our growth as the leading gastroenterology-focused specialty pharmaceutical company in the United States," Salix president and CEO Carolyn Logan said. "The creation of a larger, stronger Salix reinforces our premier position in gastroenterology and creates the opportunity for us to expand our digestive disease expertise into other key specialties."
IMS Health files with SEC for initial public offering
DANBURY, Conn. — IMS Health is looking to go public, the healthcare industry research and analytics company said.
IMS, based in Danbury, Conn., said it had filed with the Securities and Exchange Commission for a proposed initial public offering of its common stock, adding that it had not yet determined the number of shares to be offered or the price range of the offering.
The company said it planned to use the net proceeds it received to repay a portion of its long-term debt, and that a registration statement related to the securities had been filed with the SEC, but had not yet become effective.